Turning Point Brands beats Q3 profit expectations on strong demand
Reuters2026/11/09 12:41
Overview
U.S. branded consumer products maker's Q3 net sales rose 27%, beating analyst expectations
Adjusted diluted EPS for Q3 beat analyst expectations
Net income and adjusted EBITDA declined due to higher sales and marketing investments
Outlook
Company reaffirms 2026 Modern Oral gross sales guidance of $330-$350 mln
Company reaffirms 2026 Modern Oral net sales guidance of $260-$270 mln
Turning Point Brands reaffirms 2026 adjusted EBITDA forecast of $70-$80 mln
Result Drivers
MODERN ORAL GROWTH - Co said strong growth in Modern Oral products drove overall sales, with segment net sales more than doubling year-over-year
PRODUCT MIX SHIFT - Co said gross margin declined in Stoker’s segment due to a higher proportion of Modern Oral sales, which carry lower margins
HIGHER SG&A - Co attributed increased expenses to investments in Modern Oral sales and marketing and higher freight costs
Company press release: ID:nBwb2SlJ4a
Key Details
Metric |
Beat/Miss |
Actual |
Consensus Estimate |
Q3 Sales |
Beat |
$151.10 mln |
$146.67 mln (6 Analysts) |
Q3 Adjusted EPS |
Beat |
$0.41 |
$0.35 (4 Analysts) |
Q3 Gross Profit |
|
$85.18 mln |
|
Q3 Operating Income |
|
$9.87 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the tobacco peer group is "buy"
Wall Street's median 12-month price target for Turning Point Brands, Inc. is $116.00, about 76.1% above its November 6 closing price of $65.88
The stock recently traded at 30 times the next 12-month earnings vs. a P/E of 30 three months ago
Reuters Recommended Reads
Nov 9 - Ispire Technology Q1 revenue falls 9% on lower European sales
Nov 9 - Hain Celestial Q1 sales misses estimates
Nov 6 - Wendy's Q3 adjusted revenue misses estimates, hurt by weaker US demand
For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact [email protected].
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like

TEM up 10.5% in the past 24 hours

Greenbriar Names Jeffrey Ciachurski Executive Chairman
Updated: Zura Bio's mid-stage clinical trial for skin disease drug fails
